OncoMatch/Clinical Trials/NCT06758713
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
Is NCT06758713 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAR-T for multiple myeloma.
Treatment: CAR-T — This is a single center, open-label, dose-escalation/expansion clinical study to evaluate the safety and effectiveness of Fourth-Generation CAR-T, and determine the recommended dose of the CAR T-cells for patients with Multiple Myeloma，B-cell lymphoma and other hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Non-Hodgkin Lymphoma
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: CD19 positive
Required: CD7 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Exception: targeting the same molecule
Having received CAR-T therapy targeting the same molecule
Cannot have received: immunotargeted therapy
Exception: targeting the same molecules
Having received other immunotargeted therapy targeting the same molecules
Cannot have received: allogeneic hematopoietic stem cell transplantation
Having received allogeneic hematopoietic stem cell transplantation
Cannot have received: gene therapy product
prior treatment with any gene therapy product in the past three months
Lab requirements
Blood counts
White blood cell count ≥ 3.0 × 10e9/L; Absolute neutrophil ≥ 1.0 × 10e9/L; Lymphocyte count ≥ 0.5 × 10e9/L; Platelet count ≥ 50 × 10e9/L (not required for leukemia, multiple myeloma, and lymphoma)
Kidney function
Serum creatinine ≤ 2.5 mg/dl
Liver function
Serum total bilirubin (TBIL) ≤ 2.5 ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN, or 5 ULN if liver dysfunction is primarily due to tumor invasion
Cardiac function
Good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥ 55%
The clinical trial values during the screening period meet the following criteria: 1. White blood cell count ≥ 3.0 × 10e9/L; Absolute neutrophil ≥ 1.0 × 10e9/L; Lymphocyte count ≥ 0.5 × 10e9/L. (The growth factor support is allowed, but growth factor must not have been received within 7 days prior to laboratory testing); 2. Platelet count ≥ 50 × 10e9/L (No blood transfusion support within 7 days prior to laboratory tests.); Note: Patients with leukemia, multiple myeloma, and lymphoma are not subject to the above blood picture requirements; 3. Biochemical indicators Serum total bilirubin (TBIL) ≤ 2.5 ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ULN, or 5 ULN if liver dysfunction is primarily due to tumor invasion); 6. Cardiac function: Subjects must have good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥ 55%;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify